,,ii #aagth ,,congress #ast ,session ,s4 #aggc ,,in ,,the ,,senate ,,of ,,the ,,united ,,states ,may #bj1 #bjba,mr4 ,casey 7for himself and ,ms4 ,collins7 introduced the following bill2 which was read twice and referred to the ,committee on ,finance ,a ,,bill ,to amend title ,,xi of the ,social ,security ,act to establish internet website-based dashboards to allow the public to review information on spending for1 and utilization of1 prescription drugs and biologicals covered under the ,medicare and ,medicaid programs4 #a4 ,short title ,this ,act may be cited as the ,prescription ,drug ,pricing ,dashboard ,act4 #b4 ,prescription drug pricing dashboards ,part ,a of title ,,xi of the ,social ,security ,act is amended by adding at the end the following new section3 #aaej;,d4 ,prescription drug pricing dashboards 7a7 ,in general ,beginning not later than ,january #a1 #bjbb1 the ,secretary shall establish1 and annually update1 internet website-based dashboards1 through which beneficiaries1 clinicians1 researchers1 and the public can review information on spending for1 and utilization of1 prescription drugs and biologicals 7and related supplies and mechanisms of delivery7 covered under each of parts ,b and ,d of title ,,xviii and under a ,state program under title ,,xix1 including information on trends of such spending and utilization over time4 7b7 ,medicare part ,b drug and biological dashboard 7#a7 ,in general ,the dashboard established under subsection 7a7 for part ,b of title ,,xviii shall provide the information described in paragraph 7#b74 7#b7 ,information described ,the information described in this paragraph is the following information with respect to drug or biologicals covered under such part ,b3 7,a7 ,the brand name and1 if applicable1 the generic names of the drug or biological4 7,b7 ,consumer-friendly information on the uses and clinical indications of the drug or biological4 7,c7 ,the manufacturer or labeler of the drug or biological4 7,d7 ,to the extent feasible1 the following information3 7i7 ,average total spending per dosage unit of the drug or biological in the most recent #b calendar years for which data is available4 7ii7 ,the percentage change in average spending on the drug or biological per dosage unit between the most recent calendar year for which data is available and-- 7,i7 the preceding calendar year2 and 7,,ii7 the preceding #e and #aj calendar years4 7iii7 ,the annual growth rate in average spending per dosage unit of the drug or biological in the most recent #e or #aj calendar years for which data is available4 7iv7 ,total spending for the drug or biological for the most recent calendar year for which data is available4 7v7 ,the number of beneficiaries receiving the drug or biological in the most recent calendar year for which data is available4 7vi7 ,average spending on the drug per beneficiary for the most recent calendar year for which data is available4 7,e7 ,the average sales price of the drug or biological 7as determined under section #ahdg;,a7 for the most recent quarter4 7,f7 ,consumer-friendly information about the coinsurance amount for the drug or biological for beneficiaries for the most recent quarter4 ,such information shall not include coinsurance amounts for qualified medicare beneficiaries 7as defined in section #aije7p77#a774 7,g7 ,for the most recent calendar year for which data is available-- 7i7 the #ae drugs and biologicals with the highest total spending under such part2 and 7ii7 any drug or biological for which the average annual per beneficiary spending exceeds the gross spending for covered part ,d drugs at which the annual out-of-pocket threshold under section #ahfj;,d-#b7;b77#d77;,b7 would be met for the year4 7,h7 ,other information 7not otherwise prohibited in law from being disclosed7 that the ,secretary determines would provide beneficiaries1 clinicians1 researchers1 and the public with helpful information about drug and biological spending and utilization 7including trends of such spending and utilization74 7c7 ,medicare covered part ,d drug dashboard 7#a7 ,in general ,the dashboard established under subsection 7a7 for part ,d of title ,,xviii shall provide the information described in paragraph 7#b74 7#b7 ,information described ,the information described in this paragraph is the following information with respect to covered part ,d drugs under such part ,d3 7,a7 ,the information described in subparagraphs 7,a7 through 7,d7 of subsection 7b77#b74 7,b7 ,information on average annual beneficiary out-of-pocket costs below and above the annual out-of-pocket threshold under section #ahfj;,d-#b7;b77#d77;,b7 for the current plan year4 ,such information shall not include out-of-pocket costs for subsidy eligible individuals under section #ahfj;,d-#ad4 7,c7 ,information on how to access resources as described in sections #ahfj;,d-#a7;c7 and #ahea7;d74 7,d7 ,for the most recent calendar year for which data is available-- 7i7 the #ae covered part ,d drugs with the highest total spending under such part2 and 7ii7 any covered part ,d drug for which the average annual per beneficiary spending exceeds the gross spending for covered part ,d drugs at which the annual out-of-pocket threshold under section #ahfj;,d-#b7;b77#d77;,b7 would be met for the year4 7,e7 ,other information 7not otherwise prohibited in law from being disclosed7 that the ,secretary determines would provide beneficiaries1 clinicians1 researchers1 and the public with helpful information about covered part ,d drug spending and utilization 7including trends of such spending and utilization74 7d7 ,medicaid covered outpatient drug dashboard 7#a7 ,in general ,the dashboard established under subsection 7a7 for title ,,xix shall provide the information described in paragraph 7#b74 7#b7 ,information described ,the information described in this paragraph is the following information with respect to covered outpatient drugs under such title3 7,a7 ,the information described in subparagraphs 7,a7 through 7,d7 of subsection 7b77#b74 7,b7 ,for the most recent calendar year for which data is available1 the #ae covered outpatient drugs with the highest total spending under such title4 7,c7 ,other information 7not otherwise prohibited in law from being disclosed7 that the ,secretary determines would provide beneficiaries1 clinicians1 researchers1 and the public with helpful information about covered outpatient drug spending and utilization 7including trends of such spending and utilization74 7e7 ,data files ,the ,secretary shall make available the underlying data for each dashboard established under subsection 7a7 in a machine-readable format4 4